%0 Journal Article
%T A replication study of sHLA-E influence on schizophrenia and bipolar disorder.
%A Mihoub O
%A Chaaben AB
%A Boukouaci W
%A Lajnef M
%A Wu CL
%A Bouassida J
%A Saitoh K
%A Sugunasabesan S
%A Naamoune S
%A Richard JR
%A El Kefi H
%A Ben Ammar H
%A El Hechmi Z
%A Guemira F
%A Kharrat M
%A Leboyer M
%A Tamouza R
%J Encephale
%V 0
%N 0
%D 2024 May 31
%M 38824045
%F 2.787
%R 10.1016/j.encep.2024.04.004
%X <B>OBJECTIVE: </B>Schizophrenia (SZ) and bipolar disorders (BP) are chronic and severe neuropsychiatric diseases. These disorders are tightly related to immune deregulations. In the current study, we intended to replicate the previously reported involvement of the soluble HLA-E isoforms (sHLA-E) in the risk of developing the two conditions along with disease severity in a Tunisian population group.<BR><B>METHODS: </B>One hundred and twenty-four patients with schizophrenia and 121 with bipolar disorder meeting the DSM-IV criteria along 111 healthy controls were included in this present case-control study. The soluble HLA-E isoforms circulating levels were measured using the ELISA method. The statistical analyses were performed using Kruskal-Wallis and Wilcoxon rank sum tests by R software and GraphPad prism 9.<BR><B>RESULTS: </B>We found that the sHLA-E circulating levels were significantly higher in BP patients as compared to healthy controls (P<0.0001) and that such increases were mainly observed in patients during an acute phase of their disease (P<0.0001). In SZ patients, while we failed to observe an association with the levels of sHLA-E in the entire SZ sample, we found that high sHLA-E levels characterized stabilized patients in comparison with those during an acute episode (P=0.022). Finally, we did not observe any association between sHLA-E circulating levels and symptoms assessed by the classical clinical scales either in BP or SZ patients.<BR><B>CONCLUSIONS: </B>Overall, the present findings replicate in a Tunisian population group the previously demonstrated implication of sHLA-E circulating levels in the risk of developing BP or SZ in a French patient cohort. Such replication allows to consider HLA-E as a potent and true inflammatory marker in the context of the two disorders.